Meeting Impression | Modern Management of Diabetes in Cardiology: Impact of SGLT2 Inhibition on CV Outcomes and Heart FailureAugust 28, 2017 - ESC
See below to download the Meeting Impression In this educational program chaired by David Fitchett and John Deanfield, which was held at the ESC Congress 2017 in Barcelona, Spain, Naveed Sattar, John Deanfield, and Stefan Anker discussed the role of diabetes treatment in the management of heart failure, as well as novel interventions targeted to improve cardiovascular (CV) outcomes. More specifically, the epidemiology and pathophysiology of patients with diabetes and at increased CV risk were summarized, and the role of the kidney in glucose homeostasis was explained. In addition, current interventions and the unmet need of impacting CV outcomes in diabetes were discussed, the effects of SGLT2 inhibition described, as well as future strategies in these multi-risk patients.
- Prof. Naveed Sattar, Oxford, United Kingdom
- Prof. John Deanfield, University College London, United Kingdom
- Prof. Stefan Anker, Berlin, Germany
This satellite symposium was organised by the PACE Foundation and sponsored by an unrestricted educational grant of Boehringer Ingelheim/Lilly.